Calendario›REGN›Fasinumab

Fasinumab

Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With Pain Due to Osteoarthritis of the Hip or Knee

Ensayo de REGENERON PHARMACEUTICALS, INC. en Osteoarthritis, Knee · Osteoarthritis, Hip (del registro, en inglés).

Más ensayos de: Artrosis de rodilla.

Fase

Fase 2

Estado

Completado

Participantes

180

previstos

Centros

47

Fin del objetivo primario

ene 2020

fecha real

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, cuádruple ciego. Comenzó en oct 2018.

Qué mide

Change From Baseline in Peroneal Motor Nerve Conduction Velocity at Week 16 (del registro, en inglés) (inicio y semana 16)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThe primary objective of the study is to evaluate the effect of fasinumab compared to placebo on peripheral nerves in participants with pain due to Osteoarthritis (OA) of the hip or knee. The secondary objectives of the study are to: * Evaluate the efficacy of fasinumab compared to placebo in participants with pain due to OA of the hip or knee * Evaluate the safety and tolerability of fasinumab compared to placebo in participants with pain due to OA of the hip or knee * Characterize the concentrations of fasinumab in serum in participants with pain due to OA of the hip or knee * Evaluate the immunogenicity of fasinumab in participants with pain due to OA of the hip or knee.

Más ensayos de REGN

Todos los de REGN, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT03691974), actualizada en feb 2023.